Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Pandemic fears: real and imagined

“Pandemic”. Few words in the English language conjure as much fear. The mere utterance evokes images of dying patients, surgical masks, haz-mat suits, a parade of coffins, helpless doctors and nurses, as the contagion spreads, first striking down the el...
Richard (Rick) Mills | February 25, 2020 |

Quantum Economics, Negative Interest Rates and Financially Transmitted Diseases

This week the US Federal Reserve announced an emergency rate cut of 0.5% (50bps). It is part of a coordinated effort by central bankers around the world to keep the decade long bull market going a few days longer. Ultra low interest rates and ever depreciating currencie...
Marin Katusa | March 6, 2020 |

Gold vs Bitcoin: Quantum Economics and Financially Transmitted Diseases

It’s a common strategy in war. Addition by division. Put simply, adding content and flair by dividing two sides, is a very effective means of polarizing two or more sides. Cultural communists use it in their war on climate change “ You&CloseCurlyQu...
Marin Katusa | October 18, 2019 |

Financially Transmitted Diseases

I came up with Financially Transmitted Disease, or FTD TM for short, a couple of years ago. It all happened when I was having dinner with some colleagues discussing quantitative easing (QE) and negative interest rate policy (NIRP). NIRP will have the biggest impact...
Marin Katusa | September 13, 2019 |

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug

Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic ey...
Streetwise Reports | December 3, 2019 |

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases

The events in that trio are presented in a ROTH Capital Partners report. In a Feb. 3 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Albireo Pharma Inc. (ALBO:NASDAQ) plans to launch three clinical trials this year in the same num...
Streetwise Reports | February 10, 2020 |

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANG...
Streetwise Reports | October 8, 2019 |

Rare Diseases Biotech Provides Opportunity

A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company. In a March 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi indicated that the recent drop in Soleno Therapeutics Inc.'s (SL...
Streetwise Reports | March 22, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...
Dave Jackson | December 1, 2020 |
1 2 3 4 5 6 7 8 9 10 ...